• Sunshine Biopharma priced a public offering expected to raise about USD 6 million in gross proceeds.
• Deal includes 10,909,083 common units or pre-funded units priced at USD 0.55 per common unit.
• Each unit includes two Series D warrants exercisable at USD 0.66, expiring five years from issuance.
• Closing is expected around Oct. 9, 2026, subject to customary conditions.
• Net proceeds are earmarked for general corporate purposes, including working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610080800ACCESSWRNAPR_____1234227) on October 08, 2026, and is solely responsible for the information contained therein.